Skip to main content
Clinical Trials/NCT05172284
NCT05172284
Not yet recruiting
Not Applicable

Registry and Monitoring of ImmuNe-mediated Inflammatory Diseases (IMIDs) REMIND Study

I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio1 site in 1 country2,000 target enrollmentFebruary 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
ImmuNe-Mediated Inflammatory Diseases
Sponsor
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Enrollment
2000
Locations
1
Primary Endpoint
Registry of ImmuNe-mediated inflammatory Diseases (IMIDs)
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

Formation of a registry of IMID patients to assess the evolution of resistance to conventional and target therapies. This aim is achieved by evaluating the achievement of PASI 50 and PASI 75 scores at week 16 from the start of treatment.

Registry
clinicaltrials.gov
Start Date
February 2022
End Date
December 2026
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients with a diagnosis of IMID.
  • Patients of any age, including minors.
  • Patients treated with approved medications for the condition in question and/or phototherapy.
  • Patients who agree to sign informed consent.

Exclusion Criteria

  • Patients without a diagnosis of IMID.
  • Patients who do not consent to sign informed consent.

Outcomes

Primary Outcomes

Registry of ImmuNe-mediated inflammatory Diseases (IMIDs)

Time Frame: 15 years

Formation of a registry of IMID patients to assess the evolution of resistance to conventional and target therapies.

Secondary Outcomes

  • PASI 75(15 years)
  • PASI 50(15 years)

Study Sites (1)

Loading locations...

Similar Trials